Roxana Gutiérrez-Vidal, Joel Vega-Badillo, Laura M. Reyes-Fermín, Hugo A. Hernández-Pérez, Fausto Sánchez-Muñoz, Guadalupe S. López-Álvarez, Elena Larrieta-Carrasco, Itzel Fernández-Silva, Nahum Méndez-Sánchez, Armando R. Tovar, Hugo Villamil-Ramírez, Ana M. Mejía-Domínguez, Teresa Villarreal-Molina, Rogelio Hernández-Pando, Francisco Campos-Pérez, Carlos A. Aguilar-Salinas, Samuel Canizales-Quinteros
Background and aims. Secreted frizzled-related protein 5 (SFRP5) was recently described as a new adipokine protective for hepatic steatosis and other obesity-related complications in the mouse model. To date, SFRP5 expression in non-alcoholic fatty liver disease (NAFLD) has not been fully assessed in humans. We measured circulating SFRP5 levels and its expression in liver and adipose tissue, and evaluated its association with NAFLD in morbidly obese women. Material and methods. Fifty-four morbidly obese women undergoing bariatric surgery were included in the study. Liver biopsies were used for histology and hepatic triglyceride content quantification. Circulating SFRP5 levels were measured through enzyme-linked immunoabsorbent assay, and SFRP5 expression was performed in hepatic and adipose tissue (subcutaneous and visceral). Results. Although circulating SFRP5 levels showed a tendency to decrease with NAFLD progression, no significant differences were observed among non-alcoholic steatosis, steatohepatitis, and control subjects. Hepatic SFRP5 expression showed a negative correlation with hepatic triglyceride content (r = -0.349, P = 0.016 for mRNA and r = -0.291, P = 0.040 for SRFP5 protein) and ALT serum levels (r = -0.437, P = 0.001 for SRFP5 protein). In addition, hepatic SFRP5 protein levels were significantly lower in NASH than in control subjects (P = 0.006). Conclusion. This is the first study reporting an association of hepatic SFRP5 expression with NAFLD in humans.
Key words. SFRP5., Hepatic expression., NASH., Morbid obesity., Hepatic triglyceride content.